Eli Lilly Obesity Coverage Expands; M&A Activity Surges

Bristol Myers Squibb ($BMY) has seen its growth portfolio overtake its legacy products, with analysts highlighting four near-term pipeline catalysts and a dividend yield of 4.35%. The company trades at 16x P/E versus the pharma sector average of 24x, though questions remain about long-term valuation despite the attractive 4.4% yield. Moderna ($MRNA) disclosed Phase II KEYNOTE-942 oncology data for its Intismeran mRNA immunotherapy, advancing its pipeline beyond infectious disease applications. Pfizer ($PFE) continues to attract attention as a dividend stock for long-term holders, while Eli Lilly ($LLY) dominates obesity care discussions with recent CEO comments driving bullish sentiment on Wall Street.

CVS Caremark has moved to cover Eli Lilly's ($LLY) full obesity drug portfolio, including the newly approved oral therapy Foundayo, aligning with other major U.S. pharmacy benefit managers. Coverage spans both Foundayo and injectable products such as Zepbound, widening insurance access across key distribution channels and reshaping the growth and pricing outlook for obesity treatments. The decision positions $LLY as a central player in obesity care with expanded formulary presence that could accelerate adoption. Wall Street has turned increasingly bullish following recent comments from the pharmaceutical titan's CEO addressing the latest hot product in the portfolio.

Healthcare M&A activity has surged significantly, with total deal volume reaching $2.5 trillion so far this year according to recent reports. The biotech sector is expected to see increased action alongside other hot areas including casinos and home builders, signaling strong appetite for healthcare consolidation. This robust M&A environment reflects improved financing conditions and strategic interest in pipeline assets across the pharmaceutical and biotech landscape. Analysts anticipate continued dealmaking momentum as companies seek to bolster growth portfolios and address patent cliff pressures.

The global peripheral vascular devices market is projected to reach $13.22 billion by 2031, growing at a CAGR of 5.7% from $10.02 billion in 2026. Growth is fueled by increasing prevalence of vascular disorders like PAD linked to aging, diabetes, obesity, and smoking, with innovations in minimally invasive devices such as drug-coated balloons and next-generation stents boosting clinical outcomes. Abbott ($ABT) remains a focus among medical equipment makers, with analysts noting its position in the vascular devices space. Boston Scientific ($BSX) drew attention from market commentators discussing the best medical equipment makers alongside $ABT and Medtronic, with procedural shifts to ambulatory surgical centers driving market dynamics.

The global laboratory equipment services market is set to reach $35.4 billion by 2030, expanding from $18 billion in 2025 with a CAGR of 14.5%. This growth is driven by increased R&D investments, higher healthcare spending, and technological advancements across analytical equipment segments. Thermo Fisher ($TMO) leads analyst picks amid AI demand, cloud growth, and biotech expansion shaping outlooks for the laboratory services sector. The Asia-Pacific region is experiencing the highest growth rate, fueled by robust infrastructure development in China and India, with the comprehensive Gold Support Plan dominating service contract segments.

UnitedHealth Group ($UNH) faces a lawsuit filed by Massachusetts alleging the company exaggerated illness severity for Medicaid patients to obtain higher payments. The case focuses on claimed inflation of patient risk scores within the state's Medicaid program, and $UNH has denied any wrongdoing. The lawsuit introduces additional legal and reputational questions that go beyond routine operational updates, raising fresh concerns about Medicaid revenue and investor risk. Despite these challenges, $UNH continues to be compared favorably to CVS Health in dividend growth stock comparisons, with growth rather than yield cited as the deciding factor.

Tempus AI ($TEM) posted total revenue of $348.1 million in Q1, with H.C. Wainwright reducing its price target to $64 from $95 while retaining a Buy rating following the company's first-quarter results. The company ranks among potential short squeeze stocks according to recent analysis, reflecting strong revenue growth in AI-driven diagnostics and precision medicine. $TEM's performance demonstrates continued momentum in applying artificial intelligence to healthcare data analysis and personalized treatment recommendations.

The June 2026 high-growth dividend stocks list targets quality healthcare companies trading approximately 30% below intrinsic value with a 1.50% average yield, highlighting continued investor interest in undervalued pharma and biotech names. Eli Lilly ($LLY) appears on multiple screening lists as investors position for continued obesity drug growth momentum. Regeneron ($REGN) faces scrutiny as one of three Nasdaq 100 stocks flagged for potential risk amid concerns about slowing growth, increasing competition, or unsustainable valuations. Dividend-focused strategies continue to favor established pharma names including Pfizer ($PFE) for long-term holders seeking income stability.